What Cancers Cause High Ferritin Levels?

Elevated ferritin shows up across a wide range of cancers, from blood cancers like lymphoma and leukemia to solid tumors of the liver, pancreas, breast, and lung. The rise is rarely specific enough on its own to point to a particular cancer type, but the pattern is consistent: the more advanced the disease, the higher the ferritin tends to climb. What makes ferritin interesting in oncology is that it is not just a bystander marker of inflammation. Tumor cells actively manipulate iron storage for their own survival, and that biology is now shaping both how doctors predict outcomes and how researchers design new therapies.

Blood Cancers and the Strongest Ferritin Signal

Hematologic malignancies produce some of the most dramatic ferritin elevations. In malignant lymphomas, one study found elevated serum ferritin in roughly half of all patients at diagnosis, but the numbers shifted sharply by stage: about 12% of stage I patients had high ferritin, compared with 94% of those with stage IV disease.¹ The correlation tracked tumor burden rather than the specific subtype, with Hodgkin and non-Hodgkin lymphoma behaving similarly. In pediatric Hodgkin lymphoma, ferritin at diagnosis correlated with disease activity, and levels dropped meaningfully in children who achieved remission, reinforcing its usefulness as a real-time gauge of how the disease is responding to treatment.²

Acute myeloid leukemia (AML) is another major driver. Ferritin can be high at the time of first diagnosis, and it often climbs further during treatment because of the repeated blood transfusions these patients require. At six months into treatment, patients with AML were significantly more likely to have ferritin levels above 1,000 ng/mL than those with acute lymphoblastic leukemia, partly reflecting AML’s heavier transfusion burden.³ Importantly, high ferritin at diagnosis or before a stem cell transplant has been linked to worse long-term survival in AML patients, making it both a clinical marker and a prognostic signal.⁴

Multiple myeloma completes the picture among blood cancers. A retrospective study of newly diagnosed myeloma patients found that those with elevated baseline ferritin had roughly two and a half times the risk of disease progression and nearly three times the mortality risk compared with patients whose ferritin was normal.⁵

Solid Tumors That Raise Ferritin

Liver cancer sits at the top of the list among solid tumors, in part because the liver is the body’s main iron warehouse. In patients with chronic hepatitis B, men whose ferritin remained consistently above 300 ng/mL had a 50% chance of developing primary liver cancer over a follow-up of up to 17 years, compared with about 20% for men with lower levels.⁶ A separate nested case-control study found that higher ferritin was more clearly tied to death from chronic liver disease than to the development of liver cancer itself, and that the link strengthened in people who drank alcohol or were infected with hepatitis C.⁷ This is worth noting because it shows ferritin is not always a clean cancer marker in the liver. It can reflect the underlying disease (cirrhosis, viral hepatitis) as much as or more than the tumor itself.

Pancreatic cancer also drives substantial ferritin increases. In a Taiwanese case-control study, patients with pancreatic ductal adenocarcinoma had a mean ferritin of about 608 ng/mL, more than three times the level in healthy controls. Ferritin levels also varied by tumor grade, peaking in moderately differentiated tumors.⁸ Because pancreatic cancer is notoriously hard to detect early, any circulating marker that shifts with the disease draws attention, though ferritin alone lacks the specificity to serve as a screening tool.

Breast cancer patients show elevated ferritin in both serum and tumor tissue, and higher levels correlate with worse outcomes.⁹ Research in breast tissue has found that ferritin concentrations in cancerous tissue can be several times higher than in normal or benign tissue. Beyond breast cancer, elevated serum ferritin has been reported in lung cancer, colorectal cancer, and hepatocellular carcinoma, with levels often correlating with prognosis.¹⁰ In metastatic colorectal cancer, ferritin at or above 150 ng/mL independently predicted shorter survival alongside other markers like C-reactive protein and carcinoembryonic antigen.¹¹

Why Cancer Pushes Ferritin Up

The simplest explanation is inflammation. Tumors provoke a chronic inflammatory state, and the cytokines released during that process directly stimulate ferritin production. Tumor necrosis factor alpha (TNF-alpha) and interferon-gamma, two inflammatory signaling molecules common in cancer, trigger the body to sequester iron by ramping up ferritin synthesis and pulling iron out of the bloodstream.¹² This is part of the body’s general acute-phase response, the same reaction that drives ferritin up during infection, autoimmune flares, or major tissue injury.

But there is a second, more cancer-specific mechanism. TNF-alpha increases the production of the ferritin H chain through a pathway that works independently of iron itself. In lab studies, cells treated with TNF-alpha produced more ferritin H whether they were iron-loaded or iron-depleted, and the effect was additive with iron-driven ferritin production.¹³ This means a patient with cancer can have rising ferritin even when their actual iron stores are not particularly high, which is part of why ferritin alone is a poor measure of true iron status in anyone with active malignancy.

Tumor cells themselves also produce ferritin. Pan-cancer analyses have shown that the gene coding for ferritin heavy chain (FTH) is upregulated across multiple cancer types compared to normal tissue.¹⁴ In breast cancer, ferritin has been localized within tumor-associated macrophages, the immune cells that infiltrate the tumor, suggesting that both the tumor and its surrounding immune environment contribute to ferritin secretion.⁹

Neuroblastoma and Ferritin in Children

In pediatric oncology, ferritin plays a particularly well-studied role in neuroblastoma, a tumor of nerve tissue that primarily affects young children. The Children’s Cancer Study Group reported that elevated ferritin at diagnosis was uncommon in early-stage neuroblastoma but appeared in more than half of children with stage IV disease. The prognostic gap was stark: children with stage III neuroblastoma and normal ferritin had a 76% progression-free survival at two years, versus just 23% for those with elevated ferritin. For stage IV patients, the numbers were 27% and 3%, respectively.¹⁵

A large International Neuroblastoma Risk Group analysis confirmed and extended these findings, showing that higher ferritin independently predicted worse event-free survival even after adjusting for age, genetic markers, and disease stage.¹⁶ Ferritin is now formally incorporated into risk-stratification systems for neuroblastoma, influencing which children receive more intensive therapy. This is one of the clearest examples of ferritin functioning as a decision-making biomarker rather than just a laboratory curiosity.

When Ferritin Climbs During Treatment, Not From the Cancer Itself

A high ferritin reading in someone with cancer does not always mean the tumor is driving it. Patients with acute leukemia and myelodysplastic syndromes receive frequent red blood cell transfusions, and each unit of blood delivers a load of iron that the body has no efficient way to excrete. This iatrogenic iron overload can push ferritin into the thousands. In one study, the accumulating iron correlated with rising liver enzyme levels, suggesting that the excess iron was damaging the liver on top of whatever the leukemia itself was doing.¹⁷

Chemotherapy-related liver injury, infections during periods of immune suppression, and general inflammatory stress from treatment all add to the picture. When oncologists see a ferritin spike in a patient who has been receiving multiple transfusions, they cannot assume it reflects disease progression without looking at the broader context, including imaging, other lab markers, and clinical trajectory.

Hemophagocytic Lymphohistiocytosis and Extreme Ferritin

Sometimes the ferritin level in a cancer patient does not just rise; it skyrockets into the tens of thousands. One condition that can cause this is hemophagocytic lymphohistiocytosis (HLH), a hyperinflammatory syndrome in which the immune system goes into overdrive. HLH can be triggered by cancers, especially lymphomas and leukemias, and its hallmarks include prolonged fever, enlarged spleen and liver, low blood counts, and extremely high ferritin.¹⁸ HLH is rare but potentially life-threatening, and a ferritin level above 10,000 ng/mL in a cancer patient should raise suspicion for this syndrome. It requires its own specific treatment alongside cancer therapy, so recognizing it quickly matters.

How Cancer Cells Use Ferritin to Survive

Beyond serving as a marker, ferritin plays a functional role in helping tumors persist and spread. Cancer cells face a particular threat from a type of cell death called ferroptosis, which is triggered by the accumulation of iron-dependent damage to cell membranes. Tumor cells that detach from their surrounding tissue, as happens during metastasis, ramp up their ferritin production. In laboratory experiments, knocking down ferritin in these detached cells made them far more vulnerable to ferroptosis-inducing compounds.¹⁹

Some cancer cells go further. Breast cancer cells, for example, can export ferritin out of the cell through tiny vesicles called exosomes, actively pumping iron away to keep intracellular free iron levels low enough to avoid ferroptosis. This pathway is driven by a protein called prominin-2, which promotes the packaging of ferritin into these export vesicles.²⁰ In liver cancer cells, forced overexpression of the ferritin heavy chain accelerated tumor proliferation and specifically protected cells from ferroptosis, though it did not shield them from conventional chemotherapy drugs.¹⁴

This is a meaningful distinction. It suggests ferritin does not make cancer cells broadly harder to kill; it specifically protects them against iron-mediated death. That insight is steering research toward strategies that target iron metabolism as a way to make tumors more vulnerable.

Turning the Iron Connection Into Therapy

If cancer cells depend on ferritin to manage iron and resist ferroptosis, stripping iron away could be therapeutic. An FDA-approved iron chelator called deferiprone, originally developed for conditions like thalassemia, has shown promise in preclinical ovarian cancer models. Depleting iron from ovarian cancer cells triggered innate immune responses, including the release of type I interferons and the activation of natural killer cells. In mice, deferiprone combined with chemotherapy prolonged survival by turning the immune system against metastatic disease.²¹

Researchers are also exploiting the ferritin molecule itself as a drug delivery vehicle. Because tumor cells overexpress receptors that bind ferritin (they need the iron), ferritin nanocages can be loaded with chemotherapy drugs and sent directly to tumors. In mouse studies, doxorubicin packed inside ferritin shells achieved more than ten times the drug concentration inside tumors compared with free doxorubicin, while significantly inhibiting tumor growth after just a single injection.²² A variation on this approach engineered ferritin nanocages with a surface peptide targeting liver cancer specifically, packing ultra-high doses of doxorubicin into the protein shell and selectively delivering them to liver tumor cells in animal experiments.²³

These therapeutic strategies are still in preclinical or early clinical stages, but they illustrate how deeply ferritin is woven into tumor biology. The same protein that flags cancer on a blood test is being repurposed to fight it.

Why Ferritin Alone Cannot Diagnose Cancer

With all this evidence linking ferritin to malignancy, it might seem like a high ferritin test should set off cancer alarm bells. In practice, it does not work that way. Ferritin is an acute-phase reactant, meaning it rises in response to a long list of non-cancerous conditions: infections, autoimmune diseases, liver disease, iron overload disorders like hemochromatosis, chronic kidney disease, heavy alcohol use, and even recent intense exercise. A ferritin level that would be worrying in context, say above 1,000 ng/mL in someone with unexplained symptoms, might be entirely expected in a patient with a known autoimmune flare or recent blood transfusions.

The challenge with liver cancer illustrates the point. In one large study, participants with the highest ferritin levels had increased risk of dying from chronic liver disease, but ferritin was not significantly associated with developing liver cancer after adjusting for other factors.⁷ The elevated ferritin reflected the diseased liver, not necessarily a growing tumor within it. Doctors evaluating a high ferritin result need to consider the full clinical picture: other blood work (iron saturation, transferrin, inflammatory markers like CRP), imaging, symptoms, and medical history. Ferritin is a piece of the puzzle, rarely the whole picture.

Childhood Leukemia and Iron Metabolism

The ferritin-cancer relationship extends to childhood acute lymphoblastic leukemia (ALL) as well. Early observations found that children grouped by their initial serum ferritin showed differences in survival, with higher ferritin associated with worse outcomes.²⁴ These findings were considered suggestive rather than definitive, as the study design could not establish ferritin as a causal factor. Still, they fit the broader pattern seen across pediatric and adult cancers: iron metabolism is disrupted early in the disease, and the degree of disruption correlates with how aggressively the cancer behaves. Whether this reflects the tumor’s direct manipulation of iron pathways or the body’s inflammatory response to a more aggressive disease, or both, remains an active area of investigation.